|Bid||8.53 x 800|
|Ask||8.56 x 800|
|Day's Range||8.32 - 8.65|
|52 Week Range||7.37 - 15.59|
|Beta (3Y Monthly)||3.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.33|
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
NEWARK, Calif., Nov. 20, 2018 -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other.
CymaBay Therapeutics, Inc. (CBAY) presented data from its ongoing Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC). Presentations were delivered during two late-breaking presentations yesterday at The Liver Meeting® 2018 hosted by the American Association for the Study of Liver Diseases, as well as multiple additional clinical and pre-clinical presentations. Seladelpar is an orally administered, potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently in development for PBC and nonalcoholic steatohepatitis (NASH).
Conference call and webcast today at 4:30p.m. ET NEWARK, Calif., Nov. 06, 2018 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) a clinical-stage biopharmaceutical company focused.
NEWARK, Calif., Oct. 30, 2018 -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other.
CymaBay Therapeutics, Inc. (CBAY), today announced that the company has initiated the seladelpar Phase 3 registration study for the treatment of Primary Biliary Cholangitis (PBC). The study is a 52-week, placEbo-coNtrolled, randomized, pHAse 3 study to evaluate the safety aNd effiCacy of sEladelpar (ENHANCE) that will be conducted in more than 20 countries spanning five continents. The study is intended to establish the efficacy and safety of seladelpar for the treatment of PBC to support the submission of a global registration dossier with health authorities to obtain approval of seladelpar.
Details the CEO buys this past week from the following companies: Allogene Therapeutics, Conagra Brands, Texas Capital Bancshares, Fastenal and CymaBay Therapeutics
NEW YORK, Oct. 10, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
NEWARK, Calif., Sept. 24, 2018-- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today ...
Are you looking for a post-summer portfolio boost? Look no further. Investment firm Oppenheimer has released a bullish report highlighting its latest Top Stock Picks for September 2018. "These are the most timely stocks in the opinion of our research analysts" stated the firm. "Each analyst was asked to contribute the one idea they considered to outperform over the next 12 months, based on their view of the company's fundamentals in the context of current market conditions." The report lists 30 top stocks. But here I focus on the seven stocks that truly stand out from the crowd. I used TipRanks' market data to cherry-pick the report's best stocks. These are the the stocks which boast a "strong buy" consensus rating from the Street. This is based on all the ratings each stock has received over the last three months. That way we have the added reassurance of knowing that these stocks score big across the board.Let's take a closer look at these hot shots now: SEE ALSO FROM KIPLINGER: 12 Top Stock Picks to Shield Your Portfolio
Investment firm Oppenheimer has just released a bullish report highlighting its latest Top Stock Picks for August-September 2018. “These are the most timely stocks in the opinion of our research analysts” stated the firm.
LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want access to our free research report on CymaBay Therapeutics, Inc. (NASDAQ: CBAY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CBAY as the Company's latest news hit the wire. On May 08, 2018, the Company announced the initiation of Phase-2b proof of concept clinical trials of seladelpar for the treatment of patients with non-alcoholic steatohepatitis (NASH). The Company started the Phase-2b study with the screening of patients for the clinical trials.